Literature DB >> 12660621

Telemedicine applications in pediatric cardiology.

C Sable1.   

Abstract

Echocardiography is often used to diagnose and exclude important cardiac diagnoses in children. Evolving telemedicine technology has the potential to improve access to echocardiography diagnoses in the intensive care unit, emergency room, and newborn nursery. The two primary modes of telemedicine practice are "store and forward" and "real-time" videoconferencing. A digital echocardiogram (often several one cardiac cycle loops) can be stored at one site and forwarded across a telemedicine network to a receiving station for review at a later time. Pediatric cardiologists often favor "real-time" telemedicine because of the ability to guide sonographers with limited experience in congenital heart disease. A complete telemedicine system requires a modified computer, a low- or high-speed connection, and telemedicine inputs. Several adult and pediatric clinical studies have shown telemedicine to be accurate, improve patient care, be cost-effective, enhance echocardiogram quality and sonographer proficiency, and promote practice expansion. Obstacles to widespread implementation of telemedicine include lack of standardization of telemedicine components, confusing legal issues and licensure requirements, and poor reimbursement.

Entities:  

Mesh:

Year:  2003        PMID: 12660621

Source DB:  PubMed          Journal:  Minerva Pediatr        ISSN: 0026-4946            Impact factor:   1.312


  2 in total

Review 1.  Addressing health disparities in rural communities using telehealth.

Authors:  James P Marcin; Ulfat Shaikh; Robin H Steinhorn
Journal:  Pediatr Res       Date:  2015-10-14       Impact factor: 3.756

2.  Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP): 18-month experience with telemedicine screening.

Authors:  Ruwan A Silva; Yohko Murakami; Atul Jain; Jarel Gandhi; Eleonora M Lad; Darius M Moshfeghi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-09-11       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.